

1  
2  
3  
4  
5  
6  
7

**Wrong person, place and time: viral load and contact network structure predict  
SARS-CoV-2 transmission and super-spreading events**

Ashish Goyal<sup>1</sup>, Daniel B. Reeves<sup>1</sup>, E. Fabian Cardozo-Ojeda<sup>1</sup>, Joshua T. Schiffer<sup>1,2,3\*</sup> †, Bryan  
T. Mayer<sup>1</sup> †

<sup>1</sup> Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center

<sup>2</sup> Department of Medicine, University of Washington, Seattle

<sup>3</sup> Clinical Research Division, Fred Hutchinson Cancer Research Center

† These authors contributed equally to the work.

**Corresponding author:** Joshua T. Schiffer, [jschiffe@fredhutch.org](mailto:jschiffe@fredhutch.org)

**One Sentence Summary:** We developed a coupled within-host and between-host mathematical model to identify viral shedding levels required for transmission of SARS-CoV-2 and influenza, and to explain why super-spreading events occur more commonly during SARS-CoV-2 infection.

## 8 **Abstract**

9 SARS-CoV-2 is difficult to contain because many transmissions occur during the pre-  
10 symptomatic phase of infection. Moreover, in contrast to influenza, while most SARS-CoV-2  
11 infected people do not transmit the virus to anybody, a small percentage secondarily infect large  
12 numbers of people. We designed mathematical models of SARS-CoV-2 and influenza which link  
13 observed viral shedding patterns with key epidemiologic features of each virus, including  
14 distributions of the number of secondary cases attributed to each infected person (individual  $R_0$ )  
15 and the duration between symptom onset in the transmitter and secondarily infected person  
16 (serial interval). We identify that people with SARS-CoV-2 or influenza infections are usually  
17 contagious for fewer than one day congruent with peak viral load several days after infection,  
18 and that transmission is unlikely below a certain viral load. SARS-CoV-2 super-spreader events  
19 with over 10 secondary infections occur when an infected person is briefly shedding at a very  
20 high viral load and has a high concurrent number of exposed contacts. The higher predisposition  
21 of SARS-CoV-2 towards super-spreading events is not due to its 1-2 additional weeks of viral  
22 shedding relative to influenza. Rather, a person infected with SARS-CoV-2 exposes more people  
23 within equivalent physical contact networks than a person infected with influenza, likely due to  
24 aerosolization of virus. Our results support policies that limit crowd size in indoor spaces and  
25 provide viral load benchmarks for infection control and therapeutic interventions intended to  
26 prevent secondary transmission.

## 27 **Introduction**

28

29           The SARS-CoV-2 pandemic is an ongoing tragedy that has caused 700,000 deaths and  
30           massively disrupted the global economy. The pandemic is rapidly expanding in the United States  
31           and is re-emerging focally in many countries that had previous success in limiting its spread.<sup>1</sup>

32           Two features have proven challenging in containing outbreaks. First, most transmissions  
33           occur during the pre-symptomatic phase of infection.<sup>2</sup> Underlying this observation is a highly  
34           variable incubation period, defined as time between infection and symptom onset, which often  
35           extends beyond an infected person's peak viral shedding.<sup>3</sup>

36           Second, there is substantial over-dispersion of the basic reproduction number ( $R_0$ ) for an  
37           individual infected with SARS-CoV-2,<sup>4</sup> meaning that most infected people do not transmit at all,  
38           while a minority may transmit to dozens of people, with the average, population  $R_0$  achieving a  
39           high enough level ( $>1$ ) to allow exponential growth of cases in the absence of an effective  
40           intervention.<sup>5</sup> Approximately 10-20% of infected people account for 80% of SARS-CoV-2  
41           transmissions.<sup>4,6</sup> Super-spreader events, in which the duration of contact between a single  
42           transmitter and large number of secondarily infected people is often limited to hours, are well  
43           documented.<sup>7,8</sup> This pattern is not evident for influenza which has more homogeneous individual  
44           transmissions numbers.<sup>9,10</sup> Differing shedding kinetics between the two viruses might explain  
45           this distinction; SARS-CoV-2 is often present intermittently in the upper airways for many  
46           weeks,<sup>11,12</sup> while influenza is rarely shed for more than a week.<sup>13</sup> Alternatively, SARS-CoV-2  
47           aerosolization may predispose to wider exposure networks given the presence of an infected  
48           person in a crowded indoor space.

49           Viral load is recognized as a strong determinant of transmission risk. For influenza, the  
50   dose of viral exposure is related to the probability of infection in human challenge studies,<sup>14</sup> and  
51   early treatment reduces household transmission.<sup>15,16</sup> Household shedding of human herpesvirus-6  
52   is closely linked to subsequent infection in newborns,<sup>17</sup> and infants shedding high levels of  
53   cytomegalovirus in the oropharynx predictably transmit the virus back to their mothers.<sup>18</sup>

54           The epidemiology of viral infections can also be perturbed by biomedical interventions  
55   that lower viral load at mucosal transmission surfaces. Reduction of genital herpes simplex virus-  
56   2 shedding with antiviral treatments decreases probability of transmission.<sup>19</sup> Suppressive  
57   antiretroviral therapy (ART) for HIV virtually eliminates the possibility of partner-to-partner  
58   sexual transmission and has limited community transmission dramatically.<sup>20,21</sup>

59           These concepts are relevant for SARS-CoV-2 infection and require urgent attention as the  
60   pandemic continues to wreak havoc. Early therapies that lower peak viral load may reduce the  
61   severity of COVID-19 but may also decrease the probability of transmission and of super-  
62   spreader events.<sup>22</sup> Similarly, the effectiveness of policies such as limiting mass gatherings, and  
63   enforcing mask use can be directly evaluated by their ability to reduce exposure viral load and  
64   transmission risk.<sup>23</sup> Here we developed a transmission simulation framework to capture the  
65   contribution of viral load to observed epidemiologic transmission metrics for influenza and  
66   SARS-CoV-2 and used this approach to explain why SARS-CoV-2 is predisposed to super-  
67   spreading events.

## 68 **Results**

69


70 **Overall approach.** We designed a series of steps to estimate the viral load required for SARS-  
71 CoV-2 and influenza transmission, as well as conditions required to explain the observed over-  
72 dispersion of secondary infections (*individual R0*) and frequent super-spreader events associated  
73 with SARS-CoV-2 but not influenza. This process included within-host modeling of viral loads,  
74 simulations of exposures and possible transmissions based on various transmission dose response  
75 curves, testing of various parameter sets against epidemiologic data and exploratory analyses  
76 with the best fitting model (**Fig S1**).

77

78 **Within-host mathematical model of SARS CoV-2 shedding.** First, we used our previously  
79 developed within-host mathematical model (equations in the **Methods**),<sup>24</sup> to generate plausible  
80 viral load patterns in the upper airway of an infected person or *transmitter* who could potentially  
81 transmit the virus to others (**Fig 1, Fig S2a**). Briefly, the model captures observed upper airway  
82 viral kinetics from 25 people from four different countries.<sup>25-28</sup> Key observed features include an  
83 early viral peak followed by a decelerating viral clearance phase, which in turn leads to a  
84 temporary plateau at a lower viral load, ultimately followed by rapid viral elimination. Our  
85 model captures these patterns by including a density dependent term for early infected cell  
86 elimination and a nonspecific acquired immune term for late infected cell elimination.

87 One limitation of our model is that only half of study participants provided longitudinal  
88 viral load data from the very early days of infection when COVID-19 is often pre-symptomatic.  
89 Therefore, the model's output is most reliable for later time points. In particular, we have somewhat  
90 limited information on viral expansion rate and duration of peak shedding. To impute possible

91 variability, we generated a set of heterogeneous shedding curves in which the viral upslope, the  
 92 downslope of viral load after peak and the viral load during plateau phase were varied (**Fig S2b**).  
 93 Overall, the model generated several distinct patterns of infection: rapid elimination after the initial  
 94 peak, a prolonged plateau phase with a low viral load, and a prolonged plateau phase with higher  
 95 viral load. We simulated the transmission model with and without imputed heterogeneity.  
 96  
 97



98  
99

100 **Fig 1. SARS-CoV-2 and influenza transmission model schematic.** In the above cartoon, the  
 101 transmitter has 2 exposure events at discrete timepoints resulting in 7 total exposure contacts and  
 102 3 secondary infections. Transmission is more likely at the first exposure event due to higher  
 103 exposure viral load. To model this process, the timing of exposure events and number of exposed  
 104 contacts is governed by a random draw from a gamma distribution which allows for heterogeneity  
 105 in number of exposed contacts per day (**Fig S3**). Viral load is sampled at the precise time of each

106 exposure event. Probability of transmission is identified based on the product of two dose curves  
107 (**Fig S2C, D**) which capture contagiousness (probability of viral passage to an exposure contact's  
108 airway) and infectiousness (probability of transmission given viral presence in the airway).  
109 Incubation period (**Fig S4**) of the transmitter and secondarily infected person is an input into each  
110 simulation and is depicted graphically. Individual  $R_0$  is an output of each simulation and is defined  
111 as the number of secondary infections generated by an infected individual. Serial interval is an  
112 output of each simulated transmission and is depicted graphically.

113

114

115 ***Transmission dose response curves.*** We defined an *exposure event* in very specific biologic terms  
116 as a discrete event consisting of sufficient contact in time and space between a transmitter and one  
117 or more uninfected persons (*exposure contacts*) to allow for the possibility of a successful  
118 transmission. We next designed hundreds of dose response curves which separately predict  
119 contagiousness (CD curves) and infectiousness (ID curves) at a certain viral dose given an  
120 exposure contact. *Contagiousness* is defined as the viral load dependent probability of passage of  
121 virus-laden droplets or airborne particles from the airways of a potential transmitter to the airway  
122 of an exposure contact. *Infectiousness* is defined as the viral load dependent probability of  
123 transmission given direct airway exposure to virus in an exposure contact. *Transmission risk* is the  
124 product of these two mechanistic probabilities derived from the ID and CD curves and results is a  
125 transmission dose (TD) response curve. Each CD or ID curve is defined by its ID50 ( $\lambda$ ) or viral  
126 load at which contagion or infection probability is 50% (**Fig S2c**), as well as its slope ( $\alpha$ ) (**Fig**  
127 **S2d**).<sup>29</sup> The TD50 is defined as viral load at which there is 50% transmission probability. We  
128 assumed equivalent curves for contagiousness and infectiousness for model fitting purposes. We  
129 also considered a simpler model with only a single TD curve (for *infectiousness*) and obtained  
130 qualitatively similar results (**Supplement and Methods**). Our model is inclusive of the hypothesis  
131 that viral load is not a key determinant of transmission when  $\alpha \ll 1$  (**Fig S2d**).

132

133 **Exposure contact rate simulations.** We introduced heterogeneity of exposure contact rates among  
134 possible transmitters by randomly selecting from a gamma distribution defined by mean number  
135 of exposure contacts per day ( $\theta$ ) and a scaling factor ( $\rho$ ) that controls daily variability (**Fig S3**).

136

137 **Transmission simulations.** For each defined exposure contact, viral load in the transmitter was  
138 sampled and transmission risk was then identified based on the product of the CD and ID curves,  
139 or the TD curve (**Fig S2e, f; Fig 1**). Based on these probabilities, we stochastically modeled  
140 whether a transmission occurred for each exposure contact. This process was repeated when there  
141 were multiple possible exposure events within a given discretized time interval and the total  
142 number of exposures and transmissions within that interval was calculated.

143 For each successful transmission, we assumed that it takes  $\tau$  days for the first infected cell  
144 to produce virus. To inform simulated values of *serial interval* (SI or time between symptom onset  
145 in the secondarily infected and transmitter), we randomly selected the *incubation period* (IP), for  
146 both the transmitter and the newly infected person, from a gamma distribution based on existing  
147 data (**Fig S4a**).<sup>3,30</sup> Incubation period was defined as time from infection to the time of the onset of  
148 symptoms, where the mean incubation for SARS-CoV-2 is 5.2 days compared to 2 days for  
149 influenza.<sup>3,9,30</sup>

150

151 **Model fitting.** In order to identify the parameter set that best recapitulated the observed data, we  
152 then simulated several hundred thousands of parameter sets with  $\sim 250$  possible TD curves  
153 defined by ID50 and CD50 ( $\lambda$ ) and slope ( $\alpha$ ), along with  $\sim 180$  combinations of the mean  
154 exposed contact rate per day ( $\theta$ ) and associated variance parameter ( $\rho$ ), and values of  $\tau \in$   
155 [0.5, 1, 2, 3] days. We aimed to identify the parameter set that best recapitulated the following



156 features of the observed epidemiologic and individual-level data for SARS-CoV-2: mean  $R_0$   
157 across individuals ( $R_0 \in [1.4, 2.5]$ ),<sup>3,4,6,31,32</sup> mean serial interval across individuals ( $SI \in$   
158  $[4.0, 4.5]$ ),<sup>3,31,33</sup> cumulative distribution functions of individual  $R_0$ ,<sup>4,6,34-36</sup> and cumulative  
159 distribution functions of serial intervals derived from SARS-CoV-2 transmission pair studies that  
160 were conducted early during the pandemic,<sup>31</sup> prior to any confounding influence of social  
161 distancing measures. Here, we define *individual  $R_0$*  as the total number of secondary  
162 transmissions from the transmitter in a fully susceptible population (**Methods**). Given that viral  
163 RNA is composed mostly of non-infectious material, we further checked the closeness of the  
164 solved ID curve with the observed relationship between viral RNA and probability of positive  
165 viral culture from a longitudinal cohort of infected people.<sup>37</sup>


166

167 ***Influenza modeling.*** Next, we performed equivalent analyses for influenza to explain the lower  
168 frequency of observed super-spreader events with this infection. Influenza viral kinetics were  
169 modelled using a previously data-validated model.<sup>38</sup> Incubation periods for influenza are lower  
170 and less variable than for SARS-CoV-2 and were randomly selected for each simulation of the  
171 model using a gamma distribution (**Fig S4b**).<sup>39</sup> We again fit the model to: mean  $R_0$  across  
172 individuals ( $R_0 \in [1.1, 1.5]$ ),<sup>40-42</sup> mean serial interval ( $SI \in [2.9, 4.3]$ ),<sup>9</sup> cumulative distribution  
173 functions of individual  $R_0$  corresponding to the 2008-2009 influenza A H1N1 pandemic with  
174 mean  $R_0=1.26$  and dispersion parameter=2.36 in the negative binomial distribution, and  
175 cumulative distribution functions of serial intervals.<sup>9,10,40</sup>

176

177 ***Model-predicted individual  $R_0$  and serial intervals for SARS-CoV-2 infection.*** A single model  
178 parameter set ( $[\alpha, \lambda, \tau, \theta, \rho] = [0.8, 10^7, 0.5, 4, 40]$ ) most closely reproduced empirically

179 observed individual  $R_0$  and serial interval histograms (**Fig 2a, c**) and cumulative distribution  
180 functions (**Fig 2b, d**). We re-ran the model to fit to a higher population  $R_0$  of 2.8 and arrived at a  
181 similar set of parameter values but with a higher daily rate of exposure contacts ( $[\alpha, \lambda, \tau, \theta, \rho] =$   
182  $[0.8, 10^{7.5}, 0.5, 20, 30]$ ). Despite assuming that each infected person sheds at a high viral load for  
183 a period of time (**Fig 1, Fig S2b**), the model captured the fact that ~75% of 10,000 simulated  
184 transmitters do not infect any other people and that each increase in the number of possible  
185 transmissions is associated with a decreasing probability (**Fig. 2a**).  
186



187  
188  
189  
190  
191  
192  
193

**Fig 2. SARS-CoV-2 transmission model fit.** **A.** Simulated and actual frequency histograms of individual  $R_0$  values, **B.** Simulated and actual cumulative distribution of individual  $R_0$  values. **C.** Simulated and actual frequency histograms of individual serial intervals, **D.** Simulated and actual cumulative distribution of individual serial intervals. **E.** Frequency distribution of simulated generation times.

194

195 SARS-CoV-2 viral load was recently measured with viral RNA levels and mapped to  
196 concurrent probability of positive viral culture in a Dutch cohort.<sup>37</sup> Our model output  
197 demonstrated a nearly equivalent infectious dose response curve if we multiplied modeled viral  
198 RNA levels by 25 (**Fig S5**): this adjustment was likely necessary because viral loads in the Dutch  
199 study participants were notably higher than those in German, Singaporean, Korean and French  
200 participants used in our intra-host model fitting.<sup>25-28,37</sup>

201 The model also generated super-spreader events with 10,000 simulated transmissions  
202 (**Fig. 2b**). If super-spreaders are defined as those who produce at least 5 secondary infections, we  
203 estimate that ~10% of all infected people and ~35% of all transmitters are super-spreaders. If  
204 super-spreaders are defined as those who produce at least 10 secondary infections, we estimate  
205 that ~6% of all infected people and ~25% of all transmitters are super-spreaders. If super-  
206 spreaders are defined as those who produce at least 20 secondary infections, we estimate that  
207 ~2.5% of all infected people and ~10% of all transmitters are super-spreaders. If super-spreaders  
208 are defined as those producing  $\geq 5$ ,  $\geq 10$ , or  $\geq 20$  secondary infections, the contribution to all  
209 secondary infections is estimated at ~85%, ~70%, or ~44%, respectively (**Table 1**).

210 The model also recapitulated the high variance of the serial interval observed within  
211 SARS-CoV-2 transmission pairs, including negative values observed in the data (**Fig 2c, d**). We  
212 next projected *generation time*, defined as the period between when an individual becomes  
213 infected and when they transmit the virus, for all transmission pairs and identified that the mean  
214 serial interval (4.4 days) provides an accurate approximation of mean generation time. However,  
215 the variance of generation time was considerably lower and by definition does not include

216 negative values. A majority of generation times fell between 4 and 7 days, compared to -5 to 12  
 217 days for the serial interval (**Fig 2e**).

218

Super-spreader definitions	SARS-CoV-2			Influenza		
	All infected people	All transmitters	Contribution of super-spreaders to transmissions	All infected people	All transmitters	Contribution of super-spreaders to transmissions
Individual $R_0 \geq 5$	~10%	~35%	~85%	~2%	~3%	~10%
Individual $R_0 \geq 10$	~6%	~25%	~70%	~0%	~0%	~0%
Individual $R_0 \geq 20$	~2.5%	~10%	~44%	~0%	~0%	~0%

219


220 **Table 1: Prevalence of super-spreaders among transmitters, and contribution of super-**  
 221 **spreading events to all SARS-CoV-2 and influenza transmissions.** Estimates are from 10,000  
 222 simulations.

223

224

225 ***Viral load thresholds for SARS-CoV-2 transmission.*** The optimized ID curve has an ID50 of  
 226  $10^7$  viral RNA copies and a moderately steep slope (**Fig 3a**). The TD50 for SARS-CoV-2 was  
 227 slightly higher at  $10^{7.5}$  viral RNA copies (**Fig 3a**). To assess the impact of these parameters on  
 228 transmission, we performed simulations with 10,000 transmitters and concluded that  
 229 transmission is very unlikely (~0.00005%) given an exposure to an infected person with an upper  
 230 airway viral load of  $<10^4$  SARS-CoV-2 RNA copies, and unlikely (~0.002%) given an exposure  
 231 to an infected person with a viral load of  $<10^5$  SARS-CoV-2 RNA copies. On the other hand,  
 232 transmission is much more likely (39%) given an exposure to an infected person who is shedding  
 233  $>10^7$  SARS-CoV-2 RNA copies, and 75% given an exposure to an infected person with a viral

234 load of  $>10^8$  SARS-CoV-2 RNA copies. We obtain similar results (not shown) when we solve  
235 our model using the assumption of homogeneous viral load trajectories as in **Fig S2a**.  
236




237  
238  
239  
240  
241  
242  
243  
244  
245

**Fig 3. SARS-CoV-2 transmission probability as a function of shedding. A.** Optimal infectious dose (ID) response curve (infection risk =  $P_i$ ) and transmission dose (TD) response curve (transmission risk =  $P_i * P_i$ ) curves for SARS-CoV-2. Transmission probability is a product of two probabilities, contagiousness and infectiousness (**Fig 1**). **B-D.** Three simulated viral shedding curves. Heat maps represent risk of transmission at each shedding timepoint given an exposed contact with an uninfected person at that time.

246

247 **Narrow duration of high infectivity during SARS-CoV-2 infection.** We next plotted the  
248 probability of infection given an exposure to a transmitter. Under multiple shedding scenarios,  
249 the window of high probability transmission is limited to time points around peak viral load, and  
250 some heterogeneity in regard to peak infectivity is noted between people (**Fig 3b-d**). In general,  
251 infected persons are likely to be most infectious (i.e., above TD50) for a ~0.5-1.0-day period

252 between days 2 and 6 after infection. We therefore conclude that the observed wide variance in  
253 serial interval (**Fig 2c**) results primarily from the possibility of highly discrepant incubation  
254 periods between the transmitter and infected person, rather than wide variability in shedding  
255 patterns across transmitters.  
256



257  
258  
259 **Fig 4. Conditional requirements for SARS-CoV-2 superspreading events.** **A.** Heatmap  
260 demonstrating the maximum number of feasible secondary infections per day from a transmitter  
261 given an exposure viral load on log10 scale (x-axis) and number of exposed contacts per day (  
262 y-axis). The exposed contact network allows a maximum of 150 exposed contacts per day (black  
263 dotted line) which is sufficient for multiple transmissions from a single person per day. **B.** 10,000  
264 simulated transmitters followed for 30 days. The white space is a parameter space with no  
265 transmissions. Each dot represents the number of secondary transmissions from a transmitter per  
266 day. Input variables are log10 SARS-CoV-2 on the start of that day and number of contact  
267 exposures per day for the transmitter. There are 1,154,001 total exposure contacts and 15,992  
268 total infections. **C.** 10,000 simulated infections with percent of infections due to exposure viral  
269 load binned in intervals of 0.5 intervals on log10 scale (x-axis) and number of exposed contacts  
270 (y-axis).

271

272

273 **Requirements for SARS CoV-2 super-spreader events.** The solved value for exposed contact  
274 network heterogeneity ( $\rho$ ) is 40 indicating high variability in day-to-day exposure contact rates  
275 (**Fig S3d**) with a high average number of exposed contacts per day ( $\theta=4$ ). We generated a heat  
276 map from our TD curve to identify conditions required for super-spreader events which included  
277 viral load exceeding  $10^7$  SARS CoV-2 RNA copies and a high number of exposure contacts on  
278 that day. We observed an inflection point between  $10^6$  and  $10^7$  SARS CoV-2 RNA copies where

279 large increases in the number of daily exposure contacts had a more limited impact on increasing  
280 the number of transmissions from a single person (**Fig 4a**). The exposure contact network  
281 occasionally resulted in days with  $\geq 150$  exposure contacts per day, which may allow an  
282 extremely high number of secondary infections from a single person (**Fig 4a**).


283 We next plotted transmission events simulated on a daily basis over 30 days since  
284 infection, from 10,000 transmitters, according to viral load at exposure and number of exposure  
285 contacts on that day (**Fig 4b**). Secondary transmissions to only 1-3 people occurred almost  
286 exclusively with daily numbers of exposure contacts below 10 with any exposure viral load  
287 exceeding  $10^6$  RNA copies or with higher numbers of exposure contacts per day and viral loads  
288 exceeding  $10^5$  RNA copies. Massive super-spreader events with over 50 infected people almost  
289 always occurred at viral loads exceeding  $10^7$  RNA copies with high levels of concurrent  
290 exposure contacts (**Fig 4b**).

291 We next identified that over 50% of secondary infections were associated with a  
292 transmitter who has a high number of exposed contacts (11-100 per day) and a viral load  
293 exceeding  $10^6$  RNA copies (**Fig 4c**), which is the mechanistic underpinning of why ~70% of all  
294 secondary infections arose from transmitters who produced more than 10 secondary infections  
295 (**Table 1**).

296

297 ***Model predicted individual  $R_0$  and serial intervals for influenza infection.*** A single model  
298 parameter set most closely reproduced empirically observed histograms and cumulative  
299 distribution functions for individual  $R_0$  and serial intervals for influenza:  $(\alpha, \lambda, \tau, \theta, \rho) = (0.7,$   
300  $10^{5.5}, 0-0.5, 4, 1)$ . ID50 values for influenza were lower than SARS CoV-2, but a direct  
301 comparison cannot be made because tissue culture infectious dose (TCID) has been more

302 commonly used for measurements of influenza viral load, whereas viral RNA is used for SARS-  
303 CoV-2. Nevertheless, TCID is a closer measure of infectious virus and it is thus reasonable that  
304 ID50 based on TCID for influenza would be ~30-fold lower than ID50 based on total viral RNA  
305 (infectious and non-infectious virus) for SARS-CoV-2.<sup>37</sup>  
306



307  
308

309 **Fig 5. Influenza transmission model fit.** A. Simulated and actual frequency histograms of  
310 individual  $R_0$  values, B. Simulated and actual cumulative distribution of individual  $R_0$  values. C.  
311 Simulated and actual frequency histograms of individual serial intervals, D. Simulated and actual  
312 cumulative distribution of individual serial intervals. E. Frequency distribution of simulated  
313 generation times.

314

315

316 The other notable difference was a considerably lower  $\rho$  value for influenza (**Fig S3b**),


317 denoting much less heterogeneity in the number of exposure contacts per person while the

318 average daily exposure contact was the same for both viruses (4 per day). The model captures the



319 fact that 40% of influenza infected people do not transmit to anyone else and that each increase  
320 in the number of individual transmissions is associated with a lower probability (**Fig. 5a**).  
321 Relative to SARS-CoV-2, super-spreader events involving 5 or more people were predicted to be  
322 5-fold less common overall and 10-fold less common among transmitters (~2% of all infected  
323 people and ~3% of transmitters) (**Fig. 5b, Table 1**). Super-spreaders defined as those infecting  
324  $\geq 5$  individuals contributed to only ~10% to all transmissions (**Table 1**).

325 The model also recapitulated the lower variance of serial interval for influenza relative to  
326 SARS-CoV-2 (**Fig 5c, d**). We next identified that the mean and variance of the serial interval  
327 provide good approximations of the mean and variance for generation time. A majority of  
328 generation times fell between 2 and 6 days (**Fig 5e**).




329  
330

331 **Fig 6. Influenza transmission probability as a function of shedding.** A. Optimal infectious  
332 dose (ID) response curve (infection risk =  $P_t$ ) and transmission dose (TD) response curve  
333 (transmission risk =  $P_t * P_i$ ) curves for influenza. Transmission probability is a product of two  
334 probabilities, contagiousness and infectiousness (**Fig 1**). B-D. Three simulated viral shedding  
335 curves. Heat maps represent risk of transmission at each shedding timepoint given an exposed  
336 contact with an uninfected person at that time.

337

338 ***Viral load thresholds for influenza transmission.*** Based on the optimized TD curve for  
339 influenza (**Fig 6a**), we next plotted the probability of infection given an exposure to an infected  
340 person. The TD50 for influenza was  $10^{6.1}$  TCID<sub>50</sub>/mL. Under various shedding scenarios, the  
341 window of high probability transmission was limited to time points around peak viral load (**Fig**  
342 **6b-d**). In general, infected persons were likely to be most infectious (i.e., above TD50) for a  
343 ~0.5-1.0 days period. The observed low variance in serial interval (**Fig 5c**) resulted primarily  
344 from the narrow range of incubation periods within the transmitter and secondarily infected  
345 person, as well as the limited variability in shedding patterns across transmitters.

346



347

348

349 **Fig 7. Conditional requirements for influenza super spreading events.** A. Heatmap  
350 demonstrating the maximum number of secondary infections per day feasible from a transmitter  
351 given an exposure viral load on log<sub>10</sub> scale (x-axis) and number of exposed contacts per day (y-  
352 axis). The exposed contact network allows a maximum of 15 exposed contacts per day (black  
353 dotted line) which is not sufficient for more than 15 transmissions from a single person per day.  
354 B. 10,000 simulated transmitters followed for 30 days. The white space is a parameter space with  
355 no transmissions. Each dot represents the number of secondary transmissions from a transmitter  
356 per day. Input variables are log<sub>10</sub> influenza TCID on the start of that day and number of contact  
357 exposures per day for the transmitter. There are 1,239,984 total exposure contacts and 11,141  
358 total infections. C. 10,000 simulated infections with percent of infections due to exposure viral  
359 load binned in intervals of 0.5 intervals on log<sub>10</sub> scale (x-axis) and number of exposed contacts  
360 (y-axis).

361

362 ***Determinants of influenza individual R<sub>0</sub>.*** We generated a heat map from our TD curve to

363 identify conditions governing influenza transmission to multiple people including viral load

364 exceeding  $10^6$  influenza TCID and a high number of exposure contacts per day. The contact  
365 network never resulted in days with more than 15 exposure contacts per day, which severely  
366 limited the possible number of transmissions from a single person relative to SARS-CoV-2 (**Fig**  
367 **7a, S3b**).

368 We plotted transmission events simulated on a daily basis over 30 days since infection  
369 from 10,000 transmitters according to viral load at exposure and number of exposure contacts on  
370 that day (**Fig 7b**). Secondary transmissions to fewer than 5 people accounted for 90% of  
371 infections (**Table 1**) and occurred with fewer than 10 daily exposure contacts and exposure viral  
372 loads exceeding  $10^4$  TCID. Small scale super-spreader events with 5-10 infected people almost  
373 always occurred at viral loads exceeding  $10^5$  TCID with 5-10 concurrent exposure contacts (**Fig**  
374 **7b**).


375 We next identified that over 50% of infections were associated with a transmitter who  
376 had fewer than 10 exposure contacts per day and a viral load exceeding  $10^{4.5}$  TCID (**Fig 7c**),  
377 which is why no infected person ever transmitted to more than 10 other people (**Table 1**).

378

379 *Differing exposed contact distributions, rather than viral kinetics, explain SARS CoV-2 super-*  
380 *spreader events.* We sought to explain why SARS-CoV-2 has a more over-dispersed distribution  
381 of individual  $R_0$  relative to influenza. To assess viral kinetics as a potential factor, we  
382 comparatively plotted transmission risk per exposure contact as a function of time since infection  
383 in 10,000 transmitters for each virus. The median per contact transmission risk was slightly  
384 higher for influenza; however, 75% and 95% transmission risks were marginally higher for  
385 SARS-CoV-2 compared to influenza with slightly higher peak transmission risk, and a longer tail  
386 of low transmission risk beyond 7 days (**Fig 8a**). The transmission risk was considerably higher

387 for the 25% of simulated SARS-CoV-2 infections with the highest viral loads, suggesting that a  
388 substantial subset of infected people may be more pre-disposed to super-spreading. When plotted  
389 as time since onset of symptoms, the variability in transmission potential was considerably larger  
390 for persons with high SARS-CoV-2 viral load, owing to the variable incubation period of this  
391 virus (**Fig 8b**).

392



393  
394

395 **Fig 8. Differing transmission contact distributions, rather than viral kinetics explain SARS**  
396 **CoV-2 super spreader events. A.** Simulated transmission risk dynamics for 10,000 infected  
397 persons with SARS-CoV-2 and influenza. Solid line is median transmission risk. Dark, dotted  
398 line is transmission risk of 75<sup>th</sup> percentile viral loads, and light dotted line is transmission risk of  
399 95<sup>th</sup> percentile viral loads. **B.** Same as A but plotted as transmission risk since onset of  
400 symptoms. Highest transmission risk for SARS-CoV-2 is pre-symptoms and for influenza is  
401 post symptoms. **C.** Boxplots of duration of time spent above TD10, TD25, TD50, TD75 and  
402 TD90 for 10,000 simulated SARS-CoV-2 and influenza shedding episodes. TD10, TD25, TD50,  
403 TD75 and TD90 are viral loads at which transmission probability is 10%, 25%, 50%, 75% and  
404 90% respectively. The midlines are median values, boxes are interquartile ranges (IQR), and  
405 datapoints are outliers. Superimposed probability distributions of: **D & E.** number of  
406 transmission contacts per day, **F.** individual R0, **G.** serial interval and **H.** generation time for  
407 influenza and SARS-CoV-2.  
408

409

410 The median duration of shedding over infectivity thresholds was short and nearly  
411 equivalent for both viruses. For SARS-CoV-2 and influenza, median [range] time above ID10  
412 was 2.7 [0, 7] and 2.4 [1.6, 3.7] days respectively; median time above ID25 was 1.7 [0, 3] and  
413 1.5 [0, 2.2] days respectively; median time above ID50 was 0.8 [0, 1.3] and 0 [0, 1.3] days  
414 respectively; median time above ID75 was 0 [0, 0.4] and 0 [0, 0] days respectively; median time  
415 above ID90 was 0 [0, 0] and 0 [0, 0] days respectively. ID10, ID25 and ID50 values were more  
416 variable across SARS-CoV-2 simulations due to a minority of trajectories with prolonged  
417 moderate viral loads.

418 For SARS-CoV-2 and influenza, median [range] time above TD10 was 1.4 [0, 2.5] and  
419 1.2 [0, 2.0] days respectively; median time above TD25 was 0.8 [0, 1.3] and 0.3 [0, 1.3] days  
420 respectively; median time above TD50 was 0 [0, 0.5] and 0 [0, 0.4] days respectively; median  
421 time above TD75 was 0 [0, 0] and 0 [0, 0] days respectively. TD10, TD25 and TD50 values were  
422 more variable across SARS-CoV-2 simulations due to a minority of trajectories with prolonged  
423 moderate viral loads (**Fig 8c**).

424 We next plotted the frequency of exposure contacts per day for both viruses and noted a  
425 higher frequency of days with no exposed contacts (**Fig 8d**), but also a higher frequency of days  
426 with more than 10 exposure contacts (**Fig 8e**) for SARS-CoV-2 relative to influenza, despite an  
427 equivalent mean number of daily exposure contacts. To confirm that this distribution drives the  
428 different observed distributions of individual  $R_0$  values (**Fig 8f**), we simulated SARS-CoV-2  
429 infection with an assumed  $\rho=1$  and generated a distribution of individual  $R_0$  similar to that of  
430 influenza (**Fig S6a**). Similarly, we simulated influenza infection with an assumed  $\rho=40$  and  
431 generated a distribution of individual  $R_0$  similar to that of SARS-CoV-2 (**Fig S6b**). Under all  
432 scenarios, predicted distributions of serial interval (**Fig 8g, Fig S6**) and generation time (**Fig 8h,**  
433 **Fig S6**) were unchanged by shifts in the exposed contact network.

434  
435 ***Projections of targeted physical distancing.*** Physical distancing is a strategy to decrease  $R_0$ . We  
436 simulated a decrease in the contact rate uniformly across the population and noted a decrease in  
437 population  $R_0$  (**Fig S7a**) as well the percent of infected people who will transmit (**Fig 7b**) and  
438 become super-spreaders (**Fig S7c-d**). An approximately 40% decrease in the average exposed  
439 contact rate decreased  $R_0$  below 1 (**Fig S6a**). We further investigated whether lowering contact  
440 rate among larger groups only, in particular by banning exposure events with a high number of  
441 exposure contacts, could control the epidemic. We identified that limiting exposure contacts to  
442 no more than 5 per day is nearly equivalent to limiting exposure contacts altogether and that only  
443 a small decrease in mean exposure contact rate can achieve  $R_0 < 1$  if exposure events with less  
444 than 20 contacts are eliminated (**Fig S8**).

445

446 ***Pre-symptomatic transmission and super-spreading risk.*** Much of the highest transmission risk  
447 for SARS-CoV-2 exists in the pre-symptomatic phase (**Fig8b**) which explains why 62% of  
448 simulated transmissions occurred in the pre-symptomatic phase for SARS-CoV-2, compared to  
449 10% for influenza. Similarly, 62% and 21% of SARS-CoV-2 and influenza super-spreader  
450 events with secondary transmissions  $\geq 5$  and 39% of SARS-CoV-2 super-spreader events with  
451 secondary transmissions  $R_0 \geq 10$  fell in the pre-symptomatic period.

## 452 **Discussion**

453           Our results demonstrate that SARS-CoV-2 shedding kinetics are directly linked to the  
454 virus' most fundamental epidemiologic properties. First, we identify a transmission dose  
455 response curve which specifies that a nasal viral load below  $10^5$  RNA copies is unlikely to  
456 commonly result in transmission. For SARS-CoV-2, this threshold is consistent with the overall  
457 rarity of positive cultures at these levels.<sup>37</sup> We also predict a relatively steep TD curve such that  
458 transmission becomes much more likely when shedding exceeds  $10^8$  viral RNA copies and there  
459 is an exposure contact between an infected person and susceptible person. The amount of viral  
460 RNA can be roughly converted to the probability of a positive viral culture which approximates  
461 infectiousness. Our results therefore have relevance for dosing of SARS-CoV-2 in human  
462 challenge experiments that are being considered for vaccine trials.

463           While the duration of shedding for SARS-CoV-2 is often three weeks or longer,<sup>11,12</sup> we  
464 predict that the duration of shedding above thresholds required for a moderate probability of  
465 transmission per contact is much shorter, often less than half a day, and is comparable to that of  
466 influenza. While transmission after the first week of infection is quite rare, our model is  
467 consistent with the observation that transmissions commonly occur during the pre-symptomatic  
468 phase of infection,<sup>2</sup> given the highly variable incubation period associated with SARS-CoV-2.

469           The observed high heterogeneity in serial interval is attributable almost entirely to the  
470 variable nature of the incubation period, rather than transmission occurring extremely late after  
471 infection. While our estimate for mean generation time is equivalent to that of mean serial  
472 interval, it is notable that the range of SARS-CoV-2 serial intervals is much wider than the range  
473 of generation times. This result is evident even though we built substantial heterogeneity into our  
474 viral shedding curves beyond that observed in the somewhat limited existing shedding data.



475           The finding of limited duration of SARS-CoV-2 infectivity has practical implications.  
476   First, considerable resources are being used in hospitals and skilled nursing facilities to isolate  
477   patients with persistent SARS-CoV-2 shedding. We propose that a low nasal viral load,  
478   particularly during late infection, need not justify full patient isolation procedures in the absence  
479   of aerosolizing procedures. This observation could save substantial hospital resources and  
480   valuable isolation beds during subsequent waves of infection. Similar considerations are relevant  
481   for employees wishing to return to work. Our results also suggest that time since first positive  
482   test may be predictive of lack of contagion, though more viral load kinetic studies will be needed  
483   to confirm the existing observation that viral loads after a week of infection are usually low and  
484   associated with negative viral cultures.<sup>37</sup> Finally, our conclusions are supportive of rapid, less  
485   sensitive assays which are more likely to detect infection at periods of contagion.<sup>43</sup>

486           Many of these conclusions, including specific viral load thresholds for transmission, a  
487   steep dose response curve and a maximum 2-day duration of contagion within an infected  
488   individual are equally relevant for influenza infection. One important difference is that  
489   incubation periods for influenza are far less variable which means that at the individual level, the  
490   serial interval is much more likely to be predictive of the generation time.

491           Another finding is that SARS-CoV-2 super-spreading events are dependent on a large  
492   number of exposure contacts during the relatively narrow 1-2 days window during which a ~25%  
493   subset of infected people is shedding at extremely high levels above the TD50. Because we  
494   predict that super-spreader potential may be somewhat of a generalized property of infection,  
495   rather than a characteristic of a tiny subset of infected people, this result also has practical  
496   implications. A common experience during the pandemic has been early identification of a  
497   cluster of infected people within a specific confined environment such as a senior living home,

498 crowded work environment, athletic team, or restaurant. Our results demonstrate that newly  
499 diagnosed people within small clusters may be past the peak of their super-spreading potential.  
500 At this stage, many more infections have often been established and drastic quarantine  
501 procedures should be considered. Other undiagnosed, pre-symptomatic infected people may have  
502 super-spreader potential while the known infected person is no longer contagious, highlighting  
503 the importance of effective contact tracing.

504         At the prevention level, school opening and work opening strategies should focus on  
505 severely limiting the possible number of exposure contacts per day. Where large numbers of  
506 exposure contacts are unavoidable, mandatory masking policies, perhaps with N95 masks that  
507 may more significantly lower exposure viral loads should be considered.<sup>23</sup>

508         Influenza infection is much less predisposed to super-spreader events than SARS-CoV-2.  
509 Yet, influenza shedding at levels above those required for a high probability of transmission  
510 occurs with only slightly lower frequency. Therefore, the markedly different probability of  
511 super-spreader events between the two viruses is unlikely to relate to different viral host kinetics,  
512 despite the fact that the overall duration of SARS-CoV-2 shedding exceeds duration of influenza  
513 shedding often by more than two weeks.

514         Rather, our analysis suggests that the exposure contact networks of SARS-CoV-2  
515 transmitters are highly variable relative to those of influenza. One possible explanation  
516 underlying this finding is that SARS-CoV-2 is more predisposed to airborne transmission than  
517 influenza.<sup>44</sup> Here our precise definition of an exposure contact (sufficient contact between a  
518 transmitter and an uninfected person to potentially allow transmission) is of high relevance. Our  
519 result suggests that a SARS-CoV-2 infected person in a crowded, poorly ventilated room, may  
520 generate more exposure contacts than an influenza infected person in the same room, likely

521 based on wider dispersal and / or longer airborne survival of the virus. Thus, our results suggest a  
522 possible downstream quantitative effect of airborne transmission on SARS-CoV-2 epidemiology.  
523 Another possibly important variable is that pre-symptomatic transmission, which is a common  
524 feature of SARS-CoV-2 may predispose to multiple transmissions. This prediction reinforces  
525 current public health recommendation to avoid crowded indoor spaces with poor air  
526 recirculation.

527 On the other hand, a much higher proportion of SARS-CoV-2 infected people than  
528 influenza infected people do not transmit at all. This result lacks a clear mechanistic explanation  
529 but may imply that aerosolization occurs only in a subset of infected people. One theoretical  
530 explanation is that high viral load shedding in the pre-symptomatic phase is defined by lack of  
531 cough or sneeze leading to limited spatial diffusion of virus. Alternatively, it is also possible that  
532 a proportion of infected people never shed virus at high enough viral loads to allow efficient  
533 transmission. This possibility speaks to the need for more quantitative viral load data gathered  
534 during the initial stages of infection.

535 Age cohort structure differs between the two infections, with a lower proportion of  
536 observed pediatric infections for SARS-CoV-2. If adults have more high exposure events than  
537 children, then this could also explain super-spreader events. We are less enthusiastic about this  
538 hypothesis. First, SARS-CoV-2 super-spreader events have occurred in schools and camps and  
539 would likely be more common in the absence of widespread global school closures in high  
540 prevalence regions. Second, a sufficient proportion of influenza cases occur in adults to rule out  
541 the presence of frequent large super-spreading events in this population.

542 Our analysis has important limitations. First, exposure contacts were assumed to be  
543 homogeneous and we do not capture the volume of the exposing aerosol or droplet. For instance,

544 if a large-volume droplet contains ten times more viral particles than an aerosol droplet, then the  
545 exposure could be dictated by this volume as well as the viral load of the potential transmitter. It  
546 is possible that under rare circumstances with extremely high-volume exposures, even persons  
547 with extremely low viral loads may transmit. Second, based on the quality of available data, we  
548 fit our models for SARS-CoV-2 and influenza to viral RNA and viral culture respectively.  
549 Existing data suggest that kinetics of viral RNA and culture are similar during both infections,  
550 with culture having lower sensitivity to detect virus.<sup>37</sup> Third, our intra-host model of SARS-  
551 CoV-2 was fit to heterogeneous data with different sampling techniques and PCR assays.<sup>24</sup>  
552 Moreover,  $R_0$  estimates have varied across the globe. Our estimates of TD50 are necessarily  
553 imprecise based on available data and should serve only as a conservative benchmark. Most  
554 importantly, we cannot rule out the possibility that a small minority of infected people shed at  
555 sufficient levels for transmission for much longer than has been observed to date. Fourth,  
556 contagiousness could have different dose response dynamics than viral load dependent  
557 infectiousness and may require investigation in the future upon the availability of  
558 epidemiologically relevant additional data. Finally, the model is intended to capture a general  
559 property of SARS-CoV-2 infection but is not specific for local epidemics. The degree of  $R_0$   
560 overdispersion in various countries and regions is likely to vary dramatically according to  
561 numerous factors related to social contact networks that are not explicitly captured in our model.

562 In conclusion, fundamental epidemiologic features of SARS-CoV-2 and influenza  
563 infections can be directly related to viral shedding patterns in the upper airway as well as the  
564 nature of exposure contact networks. We contend that this information should be leveraged for  
565 more nuanced public health practice in the next phase of the pandemic.

## 566 **Methods**

567

568 ***SARS-CoV-2 within-host model.*** To simulate SARS-CoV-2 shedding dynamics, we employed our  
569 previously-described viral infection model.<sup>24</sup> In this model, susceptible cells ( $S$ ) after coming into  
570 contact with SARS-CoV-2 ( $V$ ) become infected at rate  $\beta VS$ . The infected cells ( $I$ ) produce new  
571 virus at a per-capita rate  $\pi$ . The model also includes the clearance of infected cells in two ways:  
572 (1) by an innate response with density dependent rate  $\delta I^k$ ; and (2) an acquired response with rate  
573  $\frac{mE^r}{E^r + \phi^r}$  mediated by SARS-CoV-2-specific effector cells ( $E$ ). The clearance mediated by innate  
574 immunity depends on the infected cell density and is controlled by the exponent  $k$ . The Hill  
575 coefficient  $r$  parameterizes the nonlinearity of the second response and allows for rapid saturation  
576 of the killing. Parameter  $\phi$  defines the effector cell level by which killing of infected cells by  $E$  is  
577 half maximal.

578 In the model, SARS-CoV-2-specific effector cells rise after 2 stages from precursors cells  
579 ( $M_1$  and  $M_2$ ). The first precursor cell compartment ( $M_1$ ) proliferates in the presence of infection  
580 with rate  $\omega IM_1$  and differentiates into the effector cell at a per capita rate  $q$  during the next  
581 intermediate stage. Finally, effector cells die at rate  $\delta_E$ . The model is expressed as a system of  
582 ordinary differential equations:

$$\begin{aligned} \frac{dS}{dt} &= -\beta VS \\ \frac{dI}{dt} &= \beta VS - \delta I^k I - m \frac{E^r}{E^r + \phi^r} I \\ \frac{dV}{dt} &= \pi I - \gamma V \\ \frac{dM_1}{dt} &= \omega I M_1 - q M_1 \\ \frac{dM_2}{dt} &= q(M_1 - M_2) \\ \frac{dE}{dt} &= q M_2 - \delta_E E \end{aligned}$$

583

584

585 We assumed  $S(0) = 10^7$  cells/mL,  $I(0) = 1$  cells/mL,  $V(0) = \frac{\pi I(0)}{c}$  copies/mL,  $M_1(0) = 1$ ,  
586  $M_2(0) = 0$  and  $E_0 = 0$ .

587 When we introduce simulated heterogeneity in cases of SARS-CoV-2 (by increasing the  
588 standard deviation of the random effects of parameters  $\beta$  by 20,  $\delta$  by 2,  $k$  by 2 and  $\pi$  by 5 in the  
589 original distribution from<sup>24</sup>), some of the viral shedding curves suggest that viral shedding could  
590 continue for long period (over 6 weeks). Indeed, while median viral shedding duration has been  
591 estimated at 12-20 days, shedding for many months is also observed commonly.<sup>45</sup> We assumed  
592 that viral loads after day 20 drop to a exposure-level viral load level (i.e.,  $V(0)$ ) as most viral  
593 shedding observed after this point is transient and at an extremely low viral load.<sup>46</sup> The population  
594 distribution of parameters to simulate artificial SARS-CoV-2 viral shedding dynamics is provided  
595 in **Table S1**.

596

597 ***Influenza within-host model.*** To simulate viral shedding dynamics of influenza viral, we employ  
598 a model<sup>38</sup> that is a simplified version of the viral dynamics model presented for SARS-CoV-2.  
599 This model assumes  $k = 0$  and  $m = 0$  and can be expressed as a system of ordinary differential  
600 equations:

$$\begin{aligned} 601 \quad & \frac{dS}{dt} = -\beta VS \\ 602 \quad & \frac{dI}{dt} = \beta VS - \delta I \\ 603 \quad & \frac{dV}{dt} = \pi I - \gamma V \end{aligned}$$

604 Following this model,<sup>38</sup> we assumed  $S(0) = 4 \times 10^8$  cells/mL,  $I(0) = 1$  cells/mL,  $V(0) = \frac{\pi I(0)}{c}$   
605 copies/mL. To simulate artificial influenza viral shedding dynamics, we assumed the population  
606 distribution of parameters  $\text{Log}_{10}(\beta)$ ,  $\text{Log}_{10}(\pi)$ ,  $\text{Log}_{10}(\gamma)$  and  $\text{Log}_{10}(\delta)$  are -4.56 (0.17), -1.98  
607 (0.14), 0.47 (0.03) and 0.60 (0.06), respectively.

608

609 **Dose-response model.** For both viruses, to estimate the infectiousness  $P_t[V(t)]$  based on viral  
610 loads  $V(t)$ , we employed the function,  $P_t[V(t)] = \frac{V(t)^\alpha}{\lambda^\alpha + V(t)^\alpha}$ . Here,  $\lambda$  is the infectivity parameter  
611 that represents the viral load that corresponds to 50% infectiousness and 50% contagiousness,  
612 and  $\alpha$  is the Hill coefficient that controls the slope of the dose-response curve.

613

614 **Transmission Model and Reproduction number.** Our transmission model assumes that only some  
615 contacts of an infected individual with viral load dependent infectiousness are physically exposed  
616 to the virus (defined as exposure contacts), that only some exposure contacts have virus passaged  
617 to their airways (contagiousness) and that only some exposed contacts with virus in their airways  
618 become secondarily infected (successful secondary infection). Contagiousness and infectiousness  
619 are then treated as viral load dependent multiplicative probabilities with transmission risk for a  
620 single exposure contact being the product. Contagiousness is considered to be viral load dependent  
621 based on the concept that a transmitter's dispersal cloud of virus is more likely to prove contagious

622 at higher viral load, which is entirely separate from viral infectivity within the airway once a virus  
623 contacts the surface of susceptible cells.

624 We next assume that the total exposed contacts within a time step ( $\eta_{\Delta_t}$ ) is gamma  
625 distributed, i.e.  $\eta_{\Delta_t} \sim \Gamma\left(\frac{\theta}{\rho}, \rho\right) \Delta_t$ , using the average daily contact rates ( $\theta$ ) and the dispersion  
626 parameter ( $\rho$ ). To obtain the true number of exposure contacts with airway exposure to virus, we  
627 simply multiply the contagiousness of the transmitter with the total exposed contacts within a time  
628 step (i.e.,  $\zeta_t = \eta_{\Delta_t} P_t$ ).

629 Transmissions within a time step are simulated stochastically using time-dependent viral  
630 load to determine infectiousness ( $P_t$ ). Successful transmission is modelled stochastically by  
631 drawing a random uniform variable ( $U(0,1)$ ) and comparing it with infectiousness of the  
632 transmitter. In the case of successful transmission, the number of secondary infections within that  
633 time step ( $T_{\Delta_t}$ ) is obtained by the product of the infectiousness ( $P_t$ ) and the number of exposure  
634 contacts drawn from the gamma distribution ( $\zeta_t$ ). In other words, the number of secondary  
635 infections for a time step is  $T_{\Delta_t} = Ber(P_t) P_t \eta_{\Delta_t}$ . If we disregard contagiousness by assuming  $P_t =$   
636  $1$  in  $\zeta_t$ , we identify that there are little to no differences on overall results other than the emergent  
637 TD curve and optimal parameter set describing dose-response curve and exposed contact network,  
638 which no longer agrees as closely with in vitro probability of positive virus culture (**Fig S5**).<sup>37</sup>

639 We obtain the number of secondary infections from a transmitter on a daily basis noting  
640 that viral load, and subsequent risk, does not change substantially within a day. We then summed  
641 up the number of secondary infections over 30 days since the time of exposure to obtain the  
642 individual reproduction number, i.e.  $R_0 = \sum_{\Delta_t} T_{\Delta_t}$ .

643



644 ***Serial interval and generation time.*** We further assume that upon successful infection, it takes  $\tau$   
645 days for the virus to move within-host, reach infection site and produce the first infected cell.  
646 To calculate serial interval (time between the onset of symptoms of transmitter and secondarily  
647 infected person), we sample the incubation period in the transmitter and in the secondarily infected  
648 person from a gamma distribution with a shape described in the **Fig S4**.<sup>3,30</sup> In cases in which  
649 symptom onset in the newly infected person precedes symptom onset in the transmitter, the serial  
650 interval is negative; otherwise, serial interval is non-negative. We calculate generation time as the  
651 difference between the time of infection of transmitter and the time of infection of secondarily  
652 infected person.

653

654 ***Individual  $R_0$  and serial interval data for model fitting.*** There is abundance of data confirming  
655 over-dispersed  $R_0$  for SARS-CoV-2. From contact tracing of 391 SARS-CoV-2 cases in  
656 Shenzhen, China, 1286 close contacts were identified: the distribution of individual  $R_0$  values in  
657 this cohort was highly over-dispersed, with 80% of secondary infections being caused by 8-9% of  
658 infected people.<sup>6</sup> In another study, authors analyzed the contact/travel history of 135 infected cases  
659 in Tianjin, China and determined heterogeneity in the individual  $R_0$ .<sup>34</sup> Another contract tracing  
660 study also identified and characterized SARS-CoV-2 clusters in Hong Kong and estimated that  
661 20% of cases were responsible for 80% of local transmission.<sup>35</sup>

662 A modeling study that simulated observed outbreak sizes in ~40 affected countries during  
663 the early phase of epidemics also confirmed that ~80% of secondary transmissions may have been  
664 caused by a small fraction of infectious individuals (~10%).<sup>4</sup> The latter study provided the  
665 distribution of individual  $R_0$  (**Fig 2A**) that we employed for fitting purposes. Using the data on  
666 468 COVID-19 transmission events reported in mainland China, Du et al. estimated the mean

667 serial interval as well as the distribution of serial interval (**Fig 2C**).<sup>31</sup> We employed this data for  
668 fitting purposes.

669 The cumulative distribution function of individual  $R_0$  for influenza was obtained from a  
670 modeling study that simulated the transmission dynamics of seasonal influenza in Switzerland  
671 from 2003 to 2015.<sup>10</sup> We picked the parameters mean  $R_0=1.26$  and dispersion parameter=2.36 in  
672 the negative binomial distribution that corresponded to the 2008-2009 influenza A H1N1  
673 pandemic.<sup>10</sup> Another modeling study that simulated the age-specific cumulative incidence of 2009  
674 H1N1 influenza in 8 Southern Hemisphere Countries yielded similar results.<sup>40</sup> By following the  
675 household members of index cases, a study estimated the cumulative distribution of serial interval  
676 based on symptom-onset times from 14 transmission pairs.<sup>9</sup> We employed these cumulative  
677 distribution functions of individual  $R_0$  and serial interval of influenza for fitting purposes.

678

679 ***Fitting procedure.*** To estimate the values of unknown parameters in cases of SARS-CoV-2, we  
680 performed a grid search comprehensively exploring a total of ~500,000 combinations of 5  
681 parameters taking the following values,

682 (i)  $\tau \in [0.5, 1, 2, 3]$  days,

683 (ii)  $\alpha \in [0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0, 3.0, 4.0, 5.0, 10.0]$

684 (iii)  $\lambda \in [10^0, 10^{0.5}, 10^{1.0} \dots, 10^8]$

685 (iv)  $\theta \in [0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0, 3.0, 4.0, 5.0, 10.0, 20.0, 50.0]$ .

686 (v)  $\rho \in [0.0001, 0.001, 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 2.0, 5.0, 10.0,$

687  $20.0, 30.0, 40.0, 50.0, 75.0, 100, 200, 500]$ .

688 The parameter sets of  $(\lambda, \tau, \alpha, \theta)$  were simulated for 1000 infected individuals to determine how  
689 well each set generates the summary statistics of mean  $R_0$ , mean  $SI$  and the  $R_0$  histograms by  
690 following a procedure explained in **Fig S1** and below:

691 **Step A:**

- 692 1. Simulate viral load  $V(t)$  of 1,000 simulated infected individuals using **Eq. 1**
- 693 2. For each combination of  $(\lambda, \tau, \alpha, \theta, \rho)$ 
  - 694 a. For each time step  $\Delta_t$ 
    - 695 i. Compute  $P_t[V(t); \lambda, \alpha]$
    - 696 ii. Draw  $\eta_{\Delta_t} \sim \Gamma\left(\frac{\theta}{\rho}, \rho\right) \Delta_t$
    - 697 iii. Calculate  $T_{\Delta_t} = Ber(P_t)P_t\eta_{\Delta_t}$
  - 698 b. Calculate  $R_0 = \sum_{\Delta_t} T_{\Delta_t}$ 
    - 699 i. Check if calculated mean  $R_0$  is in the range:<sup>3,31</sup>
  - 700 c. Calculate Serial Interval based on  $\tau$  and incubation period
    - 701 i. Check if calculated  $SI$  is in the range in:<sup>3,31,33</sup>

702 **Step B:**

- 703 1. If the parameter combination in Step A satisfy the criteria, then
  - 704 i. Compute RSS for the obtained  $R_0$  and histogram from:<sup>4,6,34,36</sup> [Ref]

705

706 We visually checked whether our dose-response curve matched the observed probability  
707 of positive virus culture.<sup>37</sup> We assumed that viral loads derived from positive culture<sup>37</sup> can be  
708 considered equivalent to viral loads in the within-host model if divided by a positive integer. We  
709 identified an integer of 25 to provide closest fit to the empirical data (**Fig S5**).

710 We performed a global sensitivity analysis to identify which parameter variability  
711 accounted for fit to different components of the data. Only narrow ranges of  $\lambda$  permitted close fit  
712 to the mean of R0 and distribution functions of individual R0 (**Fig S9**), while a specific value for  
713  $\alpha$  was necessary to fit to mean serial interval and distribution functions of individual R0 (**Fig**  
714 **S9**). Only narrow ranges of  $\theta$  permitted close fit to the mean of R0 and distribution functions of  
715 individual R0 (**Fig S10**), while a specific value for  $\rho$  was necessary to fit to distribution functions  
716 of individual R0 (**Fig S10**).

717 To obtain TD50 ( $\lambda_T$ ) based on ID50 ( $\lambda$ ), we use the relation

$$718 \frac{1}{\left(\left(\frac{10^\lambda}{V}\right)^\alpha + 1\right)^2} = \frac{1}{\left(\frac{10^{\lambda_T}}{V}\right)^{\alpha_T} + 1} = 0.5$$

719 From solving the second half ( $\frac{1}{\left(\frac{10^{\lambda_T}}{V}\right)^{\alpha_T} + 1} = 0.5$ ), we get

$$720 V = 10^{\lambda_T}$$

721 Substituting  $V = 10^{\lambda_T}$  in the first-half, we have

$$722 \frac{1}{\left(\left(\frac{10^\lambda}{10^{\lambda_T}}\right)^\alpha + 1\right)^2} = 0.5$$

$$723 \text{ Or, } \left(\left(\frac{10^\lambda}{10^{\lambda_T}}\right)^\alpha + 1\right)^2 = 2$$

$$724 \text{ Or, } \left(\frac{10^\lambda}{10^{\lambda_T}}\right)^\alpha = \sqrt{2} - 1$$

$$725 \text{ Or, } 10^{\lambda_T \alpha} = \frac{10^{\lambda \alpha}}{\sqrt{2}-1}$$

$$726 \text{ Or, } \lambda_T = \lambda + \frac{0.38}{\alpha}$$

727 **Acknowledgements**

728

729 We are grateful to study participants from around the globe who donated critical virologic data  
730 early during the pandemic. We thank Jeroen van Kampen and Marion Koopmans for helpful  
731 discussions.

732

733 **Funding:** This study was supported by Fred Hutchinson Cancer Research Center faculty  
734 discretionary funds and by National Institute of Allergy and Infectious Diseases (grant #  
735 5R01AI121129-05).

736

737 **Author contributions:** J.T.S. and B.M. conceived the study. A.G., E.F.C., B.M. and D.B.R.  
738 assembled data, wrote all code, performed all calculations and derivations, ran the models, and  
739 analyzed output data. J.T.S. wrote the manuscript with contributions from all other authors.

740

741 **Competing interests:** The authors declare no competing interests. J.T.S. is on the trial planning  
742 committee for a Gilead funded trial of remdesivir but is not reimbursed for this activity.


743

744 **Data and materials availability:** The original data and code is shared at:  
745 [https://github.com/ashish2goyal/SARS\\_CoV\\_2\\_Super\\_Spreader\\_Event](https://github.com/ashish2goyal/SARS_CoV_2_Super_Spreader_Event)


746 **Supplementary Materials**

747

**A) Calculating Mean  $R_0$ , Mean Serial Interval and histogram of  $R_0$**




**B) Finding parameter sets**




748

749 **Fig S1. Mathematical model workflow.**



750

751 **Fig S2. Mathematical model of SARS-CoV-2 transmission dynamics.** **A.** Simulated viral load  
752 shedding tracings of possible transmitters. **B.** Simulated viral load shedding with imputed  
753 heterogeneity. **C.** Simulated infection dose (ID) response curves with variance in infectivity  
754 (ID<sub>50</sub>) and **D.** dose response slopes. **E.** Simulated transmission dose (TD) response curves with  
755 variance in infectivity (TD<sub>50</sub>) and **F.** dose response slopes. The TD response curve is a product  
756 of the infection and contagion dose response curves.



757


758

759 **Fig S3. Stochastic simulations of exposed contact frequency for varying dispersion ( $\rho$ ).** The

760 average number of exposed contacts is 4 per day in each example with imputed daily


761 heterogeneity based on an elevated value of  $\rho$  from a gamma distribution  $\sim \Gamma(4/\rho, \rho)$ .





762

763 **Fig S4. Gamma distribution functions of incubation periods. A.** SARS-CoV-2 (mean 5.2  
764 days, shape parameter =3.45 and rate =0.66) and **B.** influenza (mean 2 days, shape  
765 parameter=6.25 and scale parameter=0.32).



766

767


768 **Fig S5. Mathematical model recapitulation of relationship between SARS-CoV-2 viral load**

769 **and viral culture.** In a clinical study, probability of positive viral culture was projected against

770 SARS-CoV-2 RNA (<https://www.medrxiv.org/content/10.1101/2020.06.08.20125310v1>).

771 When we divided these PCR values by 25 (light blue line), we identified high similarity between the

772 clinical data and our projected infectiousness dose response curve (red line).



773

774

775

776


777

778

779

780

**Fig S6. Impact of changes in contact network heterogeneity on individual  $R_0$ , serial interval, and generation time. A. SARS-CoV-2, and B. influenza.** Lowering exposed contact network heterogeneity to levels observed with influenza decreases SARS-CoV-2 individual  $R_0$  over-dispersion. Increasing exposed contact network heterogeneity to levels observed with SARS-CoV-2 increases influenza  $R_0$  over-dispersion. Neither change impacts observed serial interval or estimate generation time.




781

782

783 **Fig S7. Potential impact of population physical distancing on SARS-CoV-2 epidemiology.**  
784 **A.** Mean reproductive number **B.** Percent transmitters of all infected people **C.** Percent super-  
785 spreaders (individual  $R_0 > 5$ ) of all infected people **D.** Percent super spreaders of all transmitters.  
786 Transmitters are defined as infected people who generate at least one secondary infection.

787



788

789

790 **Fig S8. Potential impact of enhanced physical distancing only within high exposure contact**


791 **networks on SARS-CoV-2 epidemiology.** Simulations assume limitation of exposed contacts

792 only among daily exposures of more than 5, 10, 20 or 50 people. Mean reproductive number

793 decreases below one with only marginal decreases in overall rate of exposure contacts when

794 contacts are limited to fewer than 20 people.


It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .



795  
796

797 **Fig S9. Sensitivity analysis of transmission curve parameter for model fit to SARS-CoV-2**  
798 **data.** Effects of varying transmission curve slope (x-axis) and TD50 for infectiousness (y-axis)  
799 on fit to **A.** Mean R0, **B.** Mean serial interval, **C.** Cumulative distribution function of individual  
800 R0, and **D.** Sum of Errors in A, B and C.

801



802

803

804 **Fig S10. Sensitivity analysis of contact network structure for model fit to SARS-CoV-2**  
805 **data.** Effects of dispersion parameter (x-axis) and average exposed contacts per day (y-axis) on  
806 fit to **A.** Mean R0, **B.** Mean serial interval, **C.** Cumulative distribution function of individual R0,  
807 and **D.** Sum of Errors in A, B and C.

$\text{Log}_{10}\beta$ (virions <sup>-1</sup> day <sup>-1</sup> )	$\delta$ (day <sup>-1</sup> cells <sup>-k</sup> )	k (-)	$\text{Log}_{10}\pi$ (log <sub>10</sub> day <sup>-1</sup> )	m (day <sup>-1</sup> cells <sup>-1</sup> )	$\text{Log}_{10}\omega$ (day <sup>-1</sup> cells <sup>-1</sup> )
-7.23	3.13	0.08	2.59	3.21	-4.55
0.2	0.02	0.02	0.05	0.33	0.01

808

809 **Table S1: Population parameter estimates for simulated SARS-CoV-2 viral shedding**  
810 **dynamics.** Parameters are from (doi: <https://doi.org/10.1101/2020.04.10.20061325>). The top row  
811 is the fixed effects (mean) and the bottom row is the standard deviation of the random effects.  
812 We also fixed  $r=10$ ,  $\delta E=1/\text{day}$ ,  $q=2.4 \times 10^{-5}/\text{day}$  and  $c=15/\text{day}$ .



813 **References**

814

815 1 <https://coronavirus.jhu.edu/map.html>.

816 2 He, X. *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat*  
817 *Med* **26**, 672-675, doi:10.1038/s41591-020-0869-5 (2020).

818 3 Ganyani, T. *et al.* Estimating the generation interval for coronavirus disease (COVID-19)  
819 based on symptom onset data, March 2020. *Euro Surveill* **25**, doi:10.2807/1560-  
820 7917.ES.2020.25.17.2000257 (2020).

821 4 Endo, A., Centre for the Mathematical Modelling of Infectious Diseases COVID-19  
822 Working Group, Abbott, S., Kucharski, A. & Funk, S. Estimating the overdispersion in  
823 COVID-19 transmission using outbreak sizes outside China. *Wellcome Open Res* **5**,  
824 doi:10.12688/wellcomeopenres.15842.3 (2020).

825 5 Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E. & Getz, W. M. Superspreading and the  
826 effect of individual variation on disease emergence. *Nature* **438**, 355-359,  
827 doi:10.1038/nature04153 (2005).

828 6 Bi, Q. *et al.* Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their  
829 close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis*,  
830 doi:10.1016/S1473-3099(20)30287-5 (2020).

831 7 L., H., P., D., I., C. & al., e. High SARS-CoV-2 Attack Rate Following Exposure at a  
832 Choir Practice — Skagit County, Washington, March 2020. . *MMWR Morb Mortal Wkly*  
833 *Rep* **69:606–610**. (2020).

834 8 Park, S. Y. *et al.* Coronavirus Disease Outbreak in Call Center, South Korea. *Emerg*  
835 *Infect Dis* **26**, 1666-1670, doi:10.3201/eid2608.201274 (2020).

- 836 9 Cowling, B. J., Fang, V. J., Riley, S., Malik Peiris, J. S. & Leung, G. M. Estimation of  
837 the serial interval of influenza. *Epidemiology* **20**, 344-347,  
838 doi:10.1097/EDE.0b013e31819d1092 (2009).
- 839 10 Brugger, J. & Althaus, C. L. Transmission of and susceptibility to seasonal influenza in  
840 Switzerland from 2003 to 2015. *Epidemics* **30**, 100373,  
841 doi:10.1016/j.epidem.2019.100373 (2020).
- 842 11 Qi, L. *et al.* Factors associated with the duration of viral shedding in adults with COVID-  
843 19 outside of Wuhan, China: a retrospective cohort study. *Int J Infect Dis* **96**, 531-537,  
844 doi:10.1016/j.ijid.2020.05.045 (2020).
- 845 12 Cao, B. *et al.* A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-  
846 19. *N Engl J Med*, doi:10.1056/NEJMoa2001282 (2020).
- 847 13 Pawelek, K. A. *et al.* Modeling within-host dynamics of influenza virus infection  
848 including immune responses. *PLoS Comput Biol* **8**, e1002588,  
849 doi:10.1371/journal.pcbi.1002588 (2012).
- 850 14 Memoli, M. J. *et al.* Validation of the wild-type influenza A human challenge model  
851 H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. *Clin*  
852 *Infect Dis* **60**, 693-702, doi:10.1093/cid/ciu924 (2015).
- 853 15 Pebody, R. G. *et al.* Use of antiviral drugs to reduce household transmission of pandemic  
854 (H1N1) 2009, United Kingdom. *Emerg Infect Dis* **17**, 990-999,  
855 doi:10.3201/eid1706.101161 (2011).
- 856 16 Goldstein, E. *et al.* Oseltamivir for treatment and prevention of pandemic influenza  
857 A/H1N1 virus infection in households, Milwaukee, 2009. *BMC Infect Dis* **10**, 211,  
858 doi:10.1186/1471-2334-10-211 (2010).

- 859 17 Mayer, B. T. *et al.* Estimating the Risk of Human Herpesvirus 6 and Cytomegalovirus  
860 Transmission to Ugandan Infants from Viral Shedding in Saliva by Household Contacts.  
861 *Viruses* **12**, doi:10.3390/v12020171 (2020).
- 862 18 Boucoiran, I. *et al.* Nonprimary Maternal Cytomegalovirus Infection After Viral  
863 Shedding in Infants. *Pediatr Infect Dis J* **37**, 627-631,  
864 doi:10.1097/INF.0000000000001877 (2018).
- 865 19 Corey, L. *et al.* Once-daily valacyclovir to reduce the risk of transmission of genital  
866 herpes. *N Engl J Med* **350**, 11-20, doi:10.1056/NEJMoa035144 (2004).
- 867 20 Rodger, A. J. *et al.* Risk of HIV transmission through condomless sex in serodifferent  
868 gay couples with the HIV-positive partner taking suppressive antiretroviral therapy  
869 (PARTNER): final results of a multicentre, prospective, observational study. *Lancet* **393**,  
870 2428-2438, doi:10.1016/S0140-6736(19)30418-0 (2019).
- 871 21 Cohen, M. S. *et al.* Antiretroviral Therapy for the Prevention of HIV-1 Transmission. *N*  
872 *Engl J Med* **375**, 830-839, doi:10.1056/NEJMoa1600693 (2016).
- 873 22 Schiffer, J. T., Johnston, C., Wald, A. & Corey, L. An Early Test-and-Treat Strategy for  
874 Severe Acute Respiratory Syndrome Coronavirus 2. *Open Forum Infect Dis* **7**, ofaa232,  
875 doi:10.1093/ofid/ofaa232 (2020).
- 876 23 Leung, N. H. L. *et al.* Respiratory virus shedding in exhaled breath and efficacy of face  
877 masks. *Nat Med* **26**, 676-680, doi:10.1038/s41591-020-0843-2 (2020).
- 878 24 Goyal, A., Cardozo-Ojeda, E. & Schiffer, J. Potency and timing of antiviral therapy as  
879 determinants of duration of SARS CoV-2 shedding and intensity of inflammatory  
880 response. *medRxiv* **2020.04.10.20061325**, doi:10.1101/2020.04.10.20061325 (2020).

- 881 25 Wölfel, R. *et al.* Virological assessment of hospitalized patients with COVID-2019.  
882 *Nature* **581**, 465-469, doi:10.1038/s41586-020-2196-x (2020).
- 883 26 Lescure, F. X. *et al.* Clinical and virological data of the first cases of COVID-19 in  
884 Europe: a case series. *Lancet Infect Dis* **20**, 697-706, doi:10.1016/S1473-3099(20)30200-  
885 0 (2020).
- 886 27 Young, B. E. *et al.* Epidemiologic Features and Clinical Course of Patients Infected With  
887 SARS-CoV-2 in Singapore. *JAMA*, doi:10.1001/jama.2020.3204 (2020).
- 888 28 Kim, J. Y. *et al.* Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in  
889 Korea. *J Korean Med Sci* **35**, e86, doi:10.3346/jkms.2020.35.e86 (2020).
- 890 29 Brouwer, A. F., Weir, M. H., Eisenberg, M. C., Meza, R. & Eisenberg, J. N. S. Dose-  
891 response relationships for environmentally mediated infectious disease transmission  
892 models. *PLoS Comput Biol* **13**, e1005481, doi:10.1371/journal.pcbi.1005481 (2017).
- 893 30 Lauer, S. A. *et al.* The Incubation Period of Coronavirus Disease 2019 (COVID-19)  
894 From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med*  
895 **172**, 577-582, doi:10.7326/M20-0504 (2020).
- 896 31 Du, Z. *et al.* Serial Interval of COVID-19 among Publicly Reported Confirmed Cases.  
897 *Emerg Infect Dis* **26**, 1341-1343, doi:10.3201/eid2606.200357 (2020).
- 898 32 World Health Organization. Statement on the meeting of the International Health  
899 Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus  
900 (2019-nCoV). (2020).
- 901 33 Nishiura, H., Linton, N. M. & Akhmetzhanov, A. R. Serial interval of novel coronavirus  
902 (COVID-19) infections. *Int J Infect Dis* **93**, 284-286, doi:10.1016/j.ijid.2020.02.060  
903 (2020).

- 904 34 Zhang, Y., Li, Y., Wang, L., Li, M. & Zhou, X. Evaluating Transmission Heterogeneity  
905 and Super-Spreading Event of COVID-19 in a Metropolis of China. *Int J Environ Res*  
906 *Public Health* **17**, doi:10.3390/ijerph17103705 (2020).
- 907 35 Dillon, A. *et al.* Clustering and superspreading potential of severe acute respiratory  
908 syndrome coronavirus 2 (SARS-CoV-2) infections in Hong Kong. *PREPRINT (Version*  
909 *1) available at Research Square*, doi:10.21203/rs.3.rs-29548/v1 (2020).
- 910 36 Miller, D. *et al.* Full genome viral sequences inform patterns of SARS-CoV-2 spread into  
911 and within Israel. *medRxiv*, 2020.2005.2021.20104521,  
912 doi:10.1101/2020.05.21.20104521 (2020).
- 913 37 van Kampen, J. J. A. *et al.* Shedding of infectious virus in hospitalized patients with  
914 coronavirus disease-2019 (COVID-19): duration and key determinants. *medRxiv*,  
915 2020.2006.2008.20125310, doi:10.1101/2020.06.08.20125310 (2020).
- 916 38 Baccam, P., Beauchemin, C., Macken, C. A., Hayden, F. G. & Perelson, A. S. Kinetics of  
917 influenza A virus infection in humans. *J Virol* **80**, 7590-7599, doi:10.1128/JVI.01623-05  
918 (2006).
- 919 39 Lessler, J. *et al.* Outbreak of 2009 pandemic influenza A (H1N1) at a New York City  
920 school. *N Engl J Med* **361**, 2628-2636, doi:10.1056/NEJMoa0906089 (2009).
- 921 40 Opatowski, L. *et al.* Transmission characteristics of the 2009 H1N1 influenza pandemic:  
922 comparison of 8 Southern hemisphere countries. *PLoS Pathog* **7**, e1002225,  
923 doi:10.1371/journal.ppat.1002225 (2011).
- 924 41 Cowling, B. J. *et al.* The effective reproduction number of pandemic influenza:  
925 prospective estimation. *Epidemiology* **21**, 842-846, doi:10.1097/EDE.0b013e3181f20977  
926 (2010).

- 927 42 Roberts, M. G. & Nishiura, H. Early estimation of the reproduction number in the  
928 presence of imported cases: pandemic influenza H1N1-2009 in New Zealand. *PLoS One*  
929 6, e17835, doi:10.1371/journal.pone.0017835 (2011).
- 930 43 Larremore, D. B. *et al.* Test sensitivity is secondary to frequency and turnaround time for  
931 COVID-19 surveillance. *medRxiv*, 2020.2006.2022.20136309,  
932 doi:10.1101/2020.06.22.20136309 (2020).
- 933 44 van Doremalen, N. *et al.* Aerosol and Surface Stability of SARS-CoV-2 as Compared  
934 with SARS-CoV-1. *N Engl J Med*, doi:10.1056/NEJMc2004973 (2020).
- 935 45 Widders, A., Broom, A. & Broom, J. SARS-CoV-2: The viral shedding vs infectivity  
936 dilemma. *Infect Dis Health*, doi:10.1016/j.idh.2020.05.002 (2020).
- 937 46 Huang, C.-G. *et al.* Relative COVID-19 viral persistence and antibody kinetics. *medRxiv*,  
938 2020.2007.2001.20143917, doi:10.1101/2020.07.01.20143917 (2020).
- 939